DaVita delivered solid Q3 2024 financial results with consolidated revenues of $3.26B and operating income of $535M, representing a 16.4% operating margin. Diluted earnings per share reached $2.50, while adjusted EPS was $2.59. Operating cash flow strengthened to $810M with free cash flow of $555M.The company completed significant debt refinancing in August, securing a $1.1B Term Loan A-1 tranche and issuing $1.0B in 6.875% senior notes. The proceeds were used to repay approximately $950M Term Loan B-1 maturing in 2026 and outstanding revolving credit. During Q3, DaVita repurchased 2.7M shares at an average price of $147.20 per share.U.S. dialysis metrics showed stable performance with 7.35M total treatments in Q3, averaging 93,048 treatments per day. Revenue per treatment increased to $394.49, up from $390.22 in Q2. The company maintained its 2024 guidance with adjusted operating income projected between $1.91B-$2.01B and adjusted EPS forecast of $9.25-$10.05.

DaVita delivered solid Q3 2024 financial results with consolidated revenues of $3.26B and operating income of $535M, representing a 16.4% operating margin. Diluted earnings per share reached $2.50, while adjusted EPS was $2.59. Operating cash flow strengthened to $810M with free cash flow of $555M.The company completed significant debt refinancing in August, securing a $1.1B Term Loan A-1 tranche and issuing $1.0B in 6.875% senior notes. The proceeds were used to repay approximately $950M Term Loan B-1 maturing in 2026 and outstanding revolving credit. During Q3, DaVita repurchased 2.7M shares at an average price of $147.20 per share.U.S. dialysis metrics showed stable performance with 7.35M total treatments in Q3, averaging 93,048 treatments per day. Revenue per treatment increased to $394.49, up from $390.22 in Q2. The company maintained its 2024 guidance with adjusted operating income projected between $1.91B-$2.01B and adjusted EPS forecast of $9.25-$10.05.